Drug-resistant tuberculosis: Pediatric guidelines

Al-Dabbagh M.
Lapphra K.
McGloin R.
Inrig K.
Schaaf H.S.
Marais B.J.
Sauve L.
Kitai I.
Kollmann T.R.
Journal Title
Journal ISSN
Volume Title
Drug-resistant Mycobacterium tuberculosis (TB) infection represents a serious and growing problem. For patients infected or suspected of being infected with multidrug or extensively drug-resistant TB, several medications have to be given simultaneously for prolonged periods. Here, we review the literature on treatment and monitoring of adverse effects of pediatric drug-resistant TB therapy in a high resource, low TB burden setting. Copyright © 2011 by Lippincott Williams & Wilkins.
drug-resistance, guidelines, Mycobacterium tuberculosis, therapy, amikacin, aminoglycoside antibiotic agent, aminosalicylic acid, ciprofloxacin, cycloserine, ethambutol, ethionamide, gatifloxacin, isoniazid, kanamycin, liver enzyme, ofloxacin, ondansetron, pyrazinamide, quinoline derived antiinfective agent, streptomycin, terizidone, tuberactinomycin, antibiotic prophylaxis, antibiotic resistance, bacterium culture, directly observed therapy, drug blood level, drug dose increase, drug efficacy, drug megadose, drug resistant tuberculosis, drug withdrawal, dysglycemia, electrolyte disturbance, extensively drug resistant tuberculosis, hearing disorder, hepatomegaly, human, hypothyroidism, immunocompetence, jaundice, liver disease, liver tenderness, liver toxicity, metabolic disorder, multidrug resistant tuberculosis, Mycobacterium tuberculosis, nephrotoxicity, nonhuman, optic neuritis, peripheral neuropathy, priority journal, recommended drug dose, review, side effect, treatment outcome, tuberculin test, unspecified side effect, vestibular disorder, vomiting, Adolescent, Antitubercular Agents, Child, Child, Preschool, Drug Therapy, Combination, Humans, Infant, Infant, Newborn, Mycobacterium tuberculosis, Pediatrics, Tuberculosis, Multidrug-Resistant
Pediatric Infectious Disease Journal